CA-VISA-INC.
26.8.2020 14:02:07 CEST | Business Wire | Press release
Visa Inc. (NYSE: V) today announced Visa Smarter Stand-in Processing (Smarter STIP), a new capability that uses real-time artificial intelligence (AI) to help financial institutions manage transaction authorizations when service disruptions occur. Using deep learning to analyze past transactions, Smarter STIP generates informed decisions to approve or decline transactions on behalf of issuers in the event that their systems go offline. Visa pioneered the use of AI and neural networks to prevent fraud—Smarter STIP builds on that track record, and is the first in a suite of new AI-powered innovations coming to VisaNet, Visa’s global processing network.
“Consumers expect instant and uninterrupted access to their funds—failure to meet that expectation can be costly,” says Jack Forestell, executive vice president and chief product officer, Visa. “Stand-in processing has always been a vital assurance to our clients that when the unexpected occurs, we’ve got their back. By adding AI, that capability becomes smarter, stronger, and more dynamic.”
Addressing the challenge of downtime
Whether it’s scheduled maintenance or an unexpected outage, service downtime is disruptive for financial institutions and their customers. When stand-in processing is not in place, the potential impacts can be profound: lost revenue due to failed transactions, poor cardholder experience resulting in call volume spikes to customer service centers, damage to reputation, and even scrutiny from regulators.
Visa’s new Smarter STIP service builds on Visa’s existing STIP capability by using deep learning to analyze past transactions down to the cardholder level. Thus the transaction decision that Smarter STIP provides is based on unique insights derived from the cardholder’s past purchasing behavior, rather than solely on static rules applied across an entire card portfolio. With this added intelligence, Visa is able to provide a transaction decision on the issuer’s behalf that more closely mirrors the issuer’s own decision making process—with the potential to decrease transaction declines for cardholders by up to 50% in some cases.1
Harnessing AI for the Payments Ecosystem
Visa Smarter STIP is one of several new real-time deep learning capabilities designed to solve long-standing challenges and pain points for buyers, sellers, and financial institutions.
These enhanced services are made possible by the investments Visa has made to optimize its core infrastructure. This includes a scalable, high-performing, GPU-based platform designed to support the rapid deployment of deep learning capabilities.
“AI is one of the most transformative technologies of our time, giving us the power to build data-driven products that deliver new levels of insight and personalization. With one of the largest and richest data sets in the world, Visa is extremely well positioned to unlock the full potential of AI for our clients and cardholders, and at massive scale,” says Rajat Taneja, president of technology at Visa. “We’ve made significant investments in our infrastructure, making it possible to harness this data more deeply across all facets of VisaNet. Our data, combined with low-latency architecture and our unique modeling capabilities, make our technology platform among the most powerful for AI.”
Global adoption already underway
Smarter STIP will be available in October 2020 and has generated interest from a range of financial institutions around the world.
“At UBS, we believe in building a better future for our customers by harnessing the power of innovation and collaboration—a continuous process that relies on innovative thinking and transformative technologies and capabilities, developed both in-house and by our partners,” says Stefan Uebelhart, Head of UBS Card Center. “We are very pleased to launch Visa’s Smarter STIP service, as this is an example where the power of collaboration, transformative technologies and innovation come together to provide an improved experience for our cardholders. In our quest to build a better future for our customers, we see Visa as a valued partner and intend to work together in the innovation space.”
“As a leader in interest-free shopping platforms in Australia and New Zealand, Latitude Financial is constantly exploring new technology and innovation so we can deliver the best possible service to our customers,” said Latitude’s Chief Commercial Officer, Paul Varro. “Visa’s Smarter STIP service helps us substantially improve transaction approval rates. This is a great outcome, cleverly bringing together AI with our historical authorisation learnings, new datasets, and Visa’s experience in transaction processing to provide a rich customer experience, all the time.”
About Smarter STIP
Visa created the Smarter STIP capability to address a key pain point for issuers and issuer processors: the suboptimal experience for cardholders during service disruptions. Visa’s novel approach to stand-in processing, recognized through a US Patent in 2019, improves on the existing STIP capability through real-time evaluation of cardholder-level features. The model relies on:
- Multiple recurrent neural network layers with millions of parameters.
- Billions of historical records to train the model, resulting in an average 95% accuracy in emulating an issuer’s likely decision in Visa’s sample tests2 .
- Continuous learning from real time transaction and outage data, allowing the service to adapt and improve as an Issuers’ behavior changes over time.
Visa Smarter STIP does not require any technical change for clients to participate. Issuers connected to Visa DPS will be enabled for Smarter STIP when the service launches globally in October 2020.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , visa.com/blog and @VisaNews .
1
Based on Visa internal analysis comparing existing and Smarter STIP approval rates of all transactions in Q1 CY2020 for a single US Issuer.
2
This number was measured by Visa’s internal simulation of the Smarter STIP model offline on transactions for all Visa BINs globally in Q4 2019. On average, the Smarter STIP model made the same approve/decline decision as the issuers 95% of the time, for transactions across all regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
